ARHGAP26

Across TCGA pan-cancer cohorts, ARHGAP26 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGAP26 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARHGAP26 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGAP26 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where ARHGAP26 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.787	0.446	.003	37	view →
PDAC	DFS	Quartile	All	0.593	0.262	.012	18	view →
GBM	OS	Median	All	0.455	0.593	.026	4	view →
UCEC	DFS	Median	All	0.965	0.845	.023	4	view →
LUAD	DFS	Median	All	0.862	0.973	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARHGAP26–CCRCC (DFS)

Open the CCRCC breakdown →